- Data from LIBERTY demonstrated sustained efficacy of Aimovig (erenumab) 140 mg in reducing monthly migraine days (MMD) at 13-24 weeks in episodic migraine patients with 2-4 prior preventive treatment failures
- At week 24, patients on Aimovig experienced a sustained reduction in physical impairment and an improved ability to participate in daily activities
- Breadth of data in patients with prior treatment failures presented at EAN reinforces Novartis’ commitment to reimagining medicine for migraine patients across the spectrum of the disease
- The additional long-term data in a population with prior treatment failures complement Aimovig’s position as the most prescribed anti CGRP, with more than 220,000 patients prescribed worldwide since launch
Basel, July 1, 2019 - Novartis, a global leader in Neuroscience, today announced that additional data of the LIBERTY Phase IIIb study will be presented at the 2019 European Academy of Neurology (EAN) annual meeting in Oslo, Norway. This open-label extension phase (OLEP) confirms Aimovig (erenumab) 140 mg decreases the number of MMD as well as migraine-specific medication days (MSMD). Patients who initiated Aimovig during the OLEP demonstrated rapid improvement in weeks 13-16 and weeks 21-24 on all efficacy parameters. Outcomes on patients’ physical impairment and ability to participate in daily activities were also assessed and showed improvement (Headache Impact Test-6 [HIT-6TM] and Migraine Physical Function Impact Diary [MPFID]).
"This new set of data results underline the long-term efficacy of Aimovig for patients who have struggled to find effective preventive therapies specifically designed for migraine," said Danny Bar-Zohar, Global Head, Neuroscience Development for Novartis Pharmaceuticals. "Being able to propose additional solutions, such as Aimovig, for patients with prior preventive treatment failures is key to help them get their lives back."